Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNI911 (Niclosamide) Inhalation Safety in Healthy Volunteers
NCT04576312Phase 1Completed
- Sponsor
- UNION therapeutics
- Start
- Jun 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of UNI911 in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by UNION therapeutics. Primary endpoint: Adverse Event Frequency. Started Jun 2020; status: completed.
02
Drugs
UNI911
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04576312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04576312.